Lilly Endowment Inc reported 1 positions worth $104.21B for the quarter ended Sep 30, 2026, down 3.9% on the prior quarter. It opened 0 new positions, added to 0, trimmed 1 and exited 0. Its largest holding is ELI LILLY & Co at 100% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
| Holding | Change | Trade Value | Weight |
|---|---|---|---|
| LLY ELI LILLY & Co | -310.0K -0.3% | $358.69M | 100% |
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LLY ELI LILLY & Co | Healthcare | 90.07M | $104.21B | 100% | -310.0K | -0.3% | Reduced | 9.57% |
Tip. Select a row to see that position’s full history at Lilly Endowment.
As of its Q3 2026 13F filing, Lilly Endowment Inc’s five largest positions were ELI LILLY & Co (LLY) at 100.0% of the reported portfolio.
Lilly Endowment Inc reported a 13F portfolio worth $104.21B across 1 positions for Q3 2026. That is down 3.9% from the previous quarter.
Its largest sales by value were ELI LILLY & Co ($358.69M). It exited 0 positions entirely.
From the Form 13F-HR reports Lilly Endowment Inc files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.